Project Grant RF1AG093773
Award Date
7/1/25
Completion Date
6/30/30
Dollars Obligated
$1.3M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Aging
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
This Project Grant award of $3,317,325.00 from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will support research to investigate the role of immune dysregulation and nerve growth factor (NGF) dysfunction in the development of Alzheimer's disease (AD) in individuals with Down syndrome (DS). The key objectives are to: 1) elucidate the relationships between immune deregulation, NGF dysmetabolism, and AD hallmarks in DS brain tissue and cell cultures; 2)...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
This $3.386 million project grant from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research at Beth Israel Deaconess Medical Center to develop a potential treatment for Down syndrome. The grantee will assess the efficiency of using a modified CRISPR approach and single nucleotide polymorphism-based guide RNA targeting to silence one of three copies of human chromosome 21 in the Tc1 mouse model of Down syndrome. If successful, this research could...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
The Trustees of the University of Pennsylvania received a $3.7 million Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director to address co-occurring conditions in individuals with Down syndrome. Funded under the Trans-NIH Research Support program (CFDA 93.310), the three-year project will test whether reducing proteostatic stress with the FDA-approved small molecule 4-phenylbutyrate can ameliorate sleep deficits, metabolic...
This $3.44 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), will fund research at the University of Massachusetts Medical School to suppress aneuploidy-associated phenotypes in Down syndrome. Specifically, the researchers will identify the mechanisms by which an extra copy of chromosome 21 affects nuclear structure and function in cells, investigate how...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $780,000 in funding to Oregon Health & Science University (OHSU) to elucidate the epigenetic mechanisms responsible for allelic inactivation of protein coding genes within the Down Syndrome Critical Region and at the Alzheimer's disease-related APP gene on chromosome 21. The goal is to establish a new paradigm for understanding the cellular and disease phenotypes...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $195,041 supports research to elucidate the role of cardiovascular disease in the development of Alzheimer's disease in individuals with Down syndrome. The 2-year project will leverage data from the Alzheimer's Biomarker Consortium for Down Syndrome to develop innovative statistical models combining Bayesian inference and machine learning. These methods will explore...
This Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the cellular and synaptic mechanisms underlying cognitive disabilities in Down syndrome. The award to the University of Colorado-Denver will utilize a novel combination of two-photon microscopy, electrophysiology, chemogenetics, and pharmacological...